Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Research clarifies that no plant called 'Nutmeg Fig' exists in scientific literature, as fig (Ficus carica) and nutmeg (Myristica fragrans) are distinct species from different botanical families. Ficus carica contains bioactive compounds like 6-O-acyl-β-D-glucosyl-β-sitosterols and anthocyanins that demonstrate anticancer, antidiabetic, and neuroprotective activities through mechanisms including CDK downregulation and cholinesterase inhibition.
Reported Benefits (Provisional)
Origin & History
Nutmeg Fig (Ficus variegata) is a tropical fruit native to the forests of Southeast Asia, particularly Indonesia, Malaysia, and the Philippines. This versatile fig is recognized for its rich prebiotic fiber content and traditional use in supporting digestive and metabolic health.
Research Narrative (Provisional)
Research, including in vitro and animal studies, suggests Nutmeg Fig's potential for enhancing digestive health, modulating the gut microbiome, and supporting blood sugar regulation. These studies highlight its rich prebiotic and polyphenol content, warranting further human clinical investigation.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Prebiotic Fibers (Inulin, Pectin) - Vitamin C, Vitamin A - Potassium, Calcium, Iron - Flavonoids (Quercetin, Catechins), Tannins, Polyphenols, Saponins, Ficin (Digestive Enzyme)
Reported Mechanism (Provisional)
Ficus carica's 6-O-acyl-β-D-glucosyl-β-sitosterols trigger cancer cell death by downregulating Bcl-2, TP53, and cyclin-dependent kinases (CDK1/5/9/10). Hydroxycinnamic acids and quercetin 3-O-rutinoside provide antioxidant activity through superoxide radical scavenging and lipid peroxidation reduction. The fruit's compounds inhibit α-glucosidase and α-amylase enzymes while upregulating PPARγ and facilitating GLUT4 translocation for glucose regulation.
Clinical Narrative (Provisional)
Current evidence for fig (Ficus carica) is predominantly preclinical, with in vitro studies showing 62.9±0.9% acetylcholinesterase inhibition and 76.9±2.2% butyrylcholinesterase inhibition by leaf extracts. Animal studies by Abdel-Rahman et al. (2021) demonstrated tumor growth inhibition using nanoparticle fig extract, though specific reduction percentages were not quantified. No randomized controlled trials in humans have been conducted to validate the digestive, metabolic, or immune benefits attributed to this botanical. The evidence base requires substantial human clinical investigation to support therapeutic claims.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.